




**Supplementary Figure 1. RNAseq QC outlier detection.** Plot depicting multidimensional scaling analysis to identify outlier RNA-seq samples in the discovery cohort (n=19). Points are labeled according to gender, and the single outlier sample is indicated (arrow).




**Supplementary Figure 2. Top thirty peanut allergen response genes (peanut genes) identified by linear mixed-effects models (Bonferroni-corrected  $P < 0.01$ ) in the discovery cohort.** Boxplots displaying  $\log_2$ -cpm expression values for the top thirty peanut genes identified by linear mixed-effects model analysis (**Table 2**) excluding LTB4R and PADI4, which are included in **Fig. 2**. Gene expression levels are from the 19 peanut allergic subjects at three time points (baseline, during challenge (two hours), and end of challenge (four hours)) for both peanut and placebo challenges.




**Supplementary Figure 3. Compositional changes in leukocyte subpopulations in peanut allergic subjects, stratified by epinephrine treatment.** Boxplots displaying estimated fractions of macrophages, neutrophils, and naïve CD4<sup>+</sup> T cells at three time points (baseline, during challenge (two hours), and end of challenge (four hours)) for both peanut and placebo challenges, after stratifying the discovery cohort into subjects who received epinephrine treatment (n=11) and those who did not (n=8).





**Supplementary Figure 4. Gene expression profiles in the replication cohort of the top thirty peanut allergen response genes (peanut genes) identified in the discovery cohort.** Boxplots displaying  $\log_2\text{-cpm}$  expression values for these genes in peanut allergic subjects (n=21) from the replication cohort at three time points (baseline, during peanut challenge (two hours), and end of peanut challenge (four hours)).



**Supplementary Figure 5. Compositional changes in leukocyte subpopulations in the replication cohort.** (A) Fractions of leukocyte subpopulations estimated from transcriptome-wide RNA-seq gene expression signatures from the replication cohort ( $n=21$ ), partitioned by time point. The order in which individuals are plotted is consistent across time/challenge groups. Changes in cell type composition associated with peanut challenge were assessed using lme models. Cell types included in the analysis are indicated in the legend, listed in ranked order according to significance. FDR values are provided for the three cell types that exhibited significant changes in response to peanut but not placebo (macrophages (M0); neutrophils; naïve  $CD4^+$  T cells). Data for these significant peanut response cell types are plotted in (B), again partitioned by time point.



**Supplementary Figure 6. Variance in gene expression explained by subject, age, and sex in the discovery cohort.** Boxplots depicting the contribution of three variables on transcriptome-wide gene expression variation observed in the discovery cohort. The percent variance explained by age and sex is relatively minimal compared to that shown for subject (i.e., individual). For context, residual variation is also plotted.



**Supplementary Figure 7. Weighted coexpression network characteristics.** (A) Scale-free topology model fit in relation to soft threshold pick, supporting beta power selection. The beta selected is indicated by the black arrow. (B) Chart depicting the number of genes in each coexpression module identified by WGCNA; each module is labeled by the color indicated on the x axis.

**Supplementary Table 1.** Basic functional annotations and references for the top 30 peanut genes identified by linear mixed-effects model analysis.

<b>Gene</b>	<b>Functional annotation</b>	<b>References*</b>
<i>PLP2</i>	Interacts with chemokine receptor CCR1; Involved in T-cell acute lymphoblastic leukemia	1; 2
<i>LY9</i>	Immunomodulatory receptor (Thymocytes/Lymphocytes); regulates T-cell differentiation;	3; 4
<i>APLP2</i>	Regulates expression of MHC class I	5
<i>AGPAT9</i>	Triglycerol synthesis; adipogenesis	6
<i>NOV</i>	Regulates inflammatory response, chemotaxis, and NF-KappaB	7
<i>DGKG</i>	Genetically associated with asthma; Macrophage differentiation	8; 9
<i>BST1</i>	B cell development; neutrophil adhesion and migration	10; 11
<i>CRK</i>	Immune regulation; NK cell-mediated cytotoxicity	12
<i>CD22</i>	Co-receptor expressed on B cells	13
<i>MOSC1</i>	Mitochondrial membrane/ enzyme	14; 15
<i>PLXDC1</i>	Transmembrane receptor for PEDF (anti angiogenic, anti-tumorigenic and neutrophilic function); cancer	16; 17
<i>PADI4</i>	Autoimmunity; inflammation	18; 19; 20
<i>FCAR</i>	IgA receptor; Immune signaling	21
<i>DDX55</i>	RNA Helicase family	22
<i>PLCG2</i>	Immune cell signaling/differentiation; inflammation; autoimmunity; immunodeficiency	23; 24
<i>SULF2</i>	Inflammation; cancer	25; 26
<i>LTB4R</i>	Immune cell signaling/recruitment; inflammation	27; 28
<i>RBP7</i>	Cellular retinol binding protein (CRBP) member	29
<i>OSCAR</i>	Immune cell (monocyte) signaling development; inflammation	30; 31
<i>MMP9</i>	Immune cell signaling/activation; inflammation	32; 33
<i>JDP2</i>	Cellular senescence and aging; Histone acetylation	34; 35
<i>ACSS2</i>	Energy generation / lipid synthesis; acetate utilization; cancer survival	36; 37; 38; 39
<i>CCDC164</i>	Cilia function	40
<i>EPHB4</i>	Thymocyte development; T cell function	41; 42
<i>C5orf39</i>	Apoptosis	43
<i>SLC26A8</i>	Anion transport; sperm motility	44; 45
<i>DIRC2</i>	Electrogenic lysosomal metabolite transporter	46
<i>BMX</i>	Immune cell signaling/differentiation; inflammation	47; 48
<i>LILRA3</i>	Immune cell receptor; antigen processing	49
<i>FCRL3</i>	Autoimmunity	50

\*See Supplementary References



**Supplementary Table 2.** Linear mixed-effects model results from the leukocyte deconvolution analysis in the discovery cohort.

Cell Type	Chi square (LRT, Time by Trial Effect)	P value (LRT, Time by Trial Effect)	FDR (LRT, Time by Trial Effect)
Macrophages.M0	13.2398	0.0013	0.0166
Neutrophils	12.7018	0.0017	0.0166
T.cells.CD4.naive	11.6912	0.0029	0.0183
NK.cells.resting	7.0826	0.0290	0.1376
T.cells.CD8	5.0077	0.0818	0.3107
B.cells.naive	3.7562	0.1529	0.4841
Macrophages.M1	2.7354	0.2547	0.6534
T.cells.regulatory.Tregs.	2.5811	0.2751	0.6534
T.cells.gamma.delta	2.3382	0.3107	0.6558
Eosinophils	1.7906	0.4085	0.7092
T.cells.CD4.memory.resting	1.6243	0.4439	0.7092
T.cells.follicular.helper	1.6063	0.4479	0.7092
Plasma.cells	1.0831	0.5818	0.8504
T.cells.CD4.memory.activated	0.4851	0.7846	0.9950
NK.cells.activated	0.2459	0.8843	0.9950
B.cells.memory	0.1894	0.9096	0.9950
Monocytes	0.1232	0.9403	0.9950
Dendritic.cells.activated	0.0968	0.9527	0.9950
Mast.cells.resting	0.0100	0.9950	0.9950

**Supplementary Table 3.** Enrichment of each coexpression module for peanut genes.

Module	Total Genes in Module	Peanut Response Genes (P<0.005) in Module	<i>P</i> value (Fisher's exact test)	Fold-Enrichment of peanut response Genes in Module
Blue	2381	1223	1.16E-304	4.105
Purple	96	18	0.05	1.499
Greenyellow	84	11	0.485	1.047
Salmon	30	2	0.904	0.533
Tan	43	1	0.997	0.186
Red	546	43	1	0.629
Black	504	36	1	0.571
Brown	1133	92	1	0.649
Magenta	111	1	1	0.072
Pink	244	7	1	0.229
Green	570	22	1	0.308
Turquoise	8388	648	1	0.617
Yellow	610	18	1	0.236

**Supplementary Table 4.** Results from key driver analysis of the peanut response module. The network contained a total of 7713 genes, of which 1477 overlapped with genes in the peanut response module (N= 2381). We report here the key drivers which had an FDR  $\leq$  0.05.

Key Driver (KD) Gene	KD in the Gene Set? (1: Yes, 0: No)	# Target Genes	# Down-stream Genes	Layer where Gene is KD	Fold Change	<i>P</i> value	FDR
<i>ECHDC3</i>	1	91	146	6	3.25	5.79x10 <sup>-31</sup>	4.47x10 <sup>-27</sup>
<i>IL1R2</i>	1	64	90	6	3.71	5.81x10 <sup>-27</sup>	4.48x10 <sup>-23</sup>
<i>CEBPD</i>	0	35	47	6	3.89	2.51x10 <sup>-16</sup>	1.94x10 <sup>-12</sup>
<i>PTENP1</i>	0	61	116	6	2.75	4.80x10 <sup>-16</sup>	3.70x10 <sup>-12</sup>
<i>LTB4R</i>	1	33	52	6	3.31	2.55x10 <sup>-12</sup>	1.97x10 <sup>-08</sup>
<i>PPP1R3D</i>	1	19	28	6	3.54	2.43x10 <sup>-08</sup>	1.87x10 <sup>-04</sup>
<i>PADI4</i>	1	18	26	6	3.62	3.54x10 <sup>-08</sup>	2.73x10 <sup>-04</sup>
<i>KLHL2</i>	1	46	114	6	2.11	1.11x10 <sup>-07</sup>	8.53x10 <sup>-04</sup>
<i>ATP11A</i>	0	23	44	6	2.73	8.24x10 <sup>-07</sup>	6.35x10 <sup>-03</sup>
<i>PHC2</i>	1	33	44	5	3.92	1.28x10 <sup>-15</sup>	9.87x10 <sup>-12</sup>
<i>FLOT2</i>	1	26	45	5	3.02	9.85x10 <sup>-09</sup>	7.60x10 <sup>-05</sup>
<i>IL18R1</i>	1	25	43	5	3.04	1.60x10 <sup>-08</sup>	1.23x10 <sup>-04</sup>
<i>HAL</i>	1	38	90	5	2.20	3.56x10 <sup>-07</sup>	2.74x10 <sup>-03</sup>
<i>HDGFRP3</i>	0	18	29	5	3.24	4.35x10 <sup>-07</sup>	3.35x10 <sup>-03</sup>
<i>PFKFB4</i>	1	16	24	5	3.48	4.68x10 <sup>-07</sup>	3.61x10 <sup>-03</sup>
<i>MAR1</i>	0	14	21	5	3.48	2.52x10 <sup>-06</sup>	1.95x10 <sup>-02</sup>
<i>MAPK14</i>	1	30	43	4	3.64	6.15x10 <sup>-13</sup>	4.74x10 <sup>-09</sup>
<i>TMCC3</i>	1	14	16	4	4.57	6.89x10 <sup>-09</sup>	5.31x10 <sup>-05</sup>
<i>EXOC6</i>	0	19	30	4	3.31	1.29x10 <sup>-07</sup>	9.98x10 <sup>-04</sup>
<i>LOC100507006</i>	0	12	15	4	4.18	5.98x10 <sup>-07</sup>	4.61x10 <sup>-03</sup>
<i>RAB36</i>	0	16	27	4	3.09	4.62x10 <sup>-06</sup>	3.56x10 <sup>-02</sup>
<i>CAMKK2</i>	1	24	31	3	4.04	3.29x10 <sup>-12</sup>	2.54x10 <sup>-08</sup>
<i>MAP2K6</i>	0	15	19	3	4.12	2.85x10 <sup>-08</sup>	2.20x10 <sup>-04</sup>
<i>GNB2</i>	1	16	27	3	3.09	4.62x10 <sup>-06</sup>	3.56x10 <sup>-02</sup>
<i>BMX</i>	1	14	16	2	4.57	6.89x10 <sup>-09</sup>	5.31x10 <sup>-05</sup>
<i>SLC9A8</i>	1	12	17	2	3.69	5.54x10 <sup>-06</sup>	4.27x10 <sup>-02</sup>

**Supplementary Table 5.** Characteristics of additional food allergic subjects whose samples were included in the weighted gene coexpression network construction

<b>Subject</b>	<b>Suspected allergen/ food challenged</b>	<b>Sex</b>	<b>Age (years)</b>	<b>Food allergen sIgE (kU<sub>a</sub>/L)</b>
FA1	Wheat	M	13	78.5
FA2	Wheat	F	10	>100
FA3	Wheat	F	9	14.3
FA4	Soy	M	6	33
FA5	Wheat	M	5	17.3
FA6	Baked Milk	M	7	18.6
FA7	Sesame	M	11	19.6

## Supplementary References

1. Lee SM, et al. PLP2/A4 interacts with CCR1 and stimulates migration of CCR1-expressing HOS cells. *Biochem Biophys Res Commun* 324, 768-772 (2004).
2. Zhu H, Miao MH, Ji XQ, Xue J, Shao XJ. miR-664 negatively regulates PLP2 and promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia. *Biochem Biophys Res Commun* 459, 340-345 (2015).
3. de la Fuente MA, et al. Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. *Blood* 97, 3513-3520 (2001).
4. Chatterjee M, et al. Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation. *J Immunol* 188, 1206-1212 (2012).
5. Peters HL, et al. Regulation of major histocompatibility complex class I molecule expression on cancer cells by amyloid precursor-like protein 2. *Immunol Res* 51, 39-44 (2011).
6. Shan D, et al. GPAT3 and GPAT4 are regulated by insulin-stimulated phosphorylation and play distinct roles in adipogenesis. *J Lipid Res* 51, 1971-1981 (2010).
7. Lin Z, et al. A novel role of CCN3 in regulating endothelial inflammation. *J Cell Commun Signal* 4, 141-153 (2010).
8. Melen E, et al. Analyses of shared genetic factors between asthma and obesity in children. *J Allergy Clin Immunol* 126, 631-637 e631-638 (2010).
9. Yamada K, Sakane F, Imai S, Tsushima S, Murakami T, Kanoh H. Regulatory role of diacylglycerol kinase gamma in macrophage differentiation of leukemia cells. *Biochem Biophys Res Commun* 305, 101-107 (2003).
10. Kaisho T, et al. BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth. *Proc Natl Acad Sci U S A* 91, 5325-5329 (1994).
11. Funaro A, et al. CD157 is an important mediator of neutrophil adhesion and migration. *Blood* 104, 4269-4278 (2004).
12. Liu D. The adaptor protein Crk in immune response. *Immunol Cell Biol* 92, 80-89 (2014).
13. Kawasaki N, Rademacher C, Paulson JC. CD22 regulates adaptive and innate immune responses of B cells. *J Innate Immun* 3, 411-419 (2011).

14. Sparacino-Watkins CE, et al. Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2. *J Biol Chem* 289, 10345-10358 (2014).
15. Klein JM, Busch JD, Potting C, Baker MJ, Langer T, Schwarz G. The mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane. *J Biol Chem* 287, 42795-42803 (2012).
16. Cheng G, et al. Identification of PLXDC1 and PLXDC2 as the transmembrane receptors for the multifunctional factor PEDF. *Elife* 3, e05401 (2014).
17. Bagley RG, et al. Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy. *Microvasc Res* 82, 253-262 (2011).
18. Suzuki A, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. *Nat Genet* 34, 395-402 (2003).
19. Snir O, et al. Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis. *Arthritis Res Ther* 16, 414 (2014).
20. Spengler J, et al. Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid. *Arthritis Rheumatol* 67, 3135-3145 (2015).
21. Morton HC, Brandtzaeg P. CD89: the human myeloid IgA Fc receptor. *Arch Immunol Ther Exp (Warsz)* 49, 217-229 (2001).
22. Schmid SR, Linder P. D-E-A-D protein family of putative RNA helicases. *Mol Microbiol* 6, 283-291 (1992).
23. Ombrello MJ, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. *N Engl J Med* 366, 330-338 (2012).
24. Wang J, Sohn H, Sun G, Milner JD, Pierce SK. The autoinhibitory C-terminal SH2 domain of phospholipase C-gamma2 stabilizes B cell receptor signalosome assembly. *Sci Signal* 7, ra89 (2014).
25. Yue X. Epithelial Deletion of Sulf2 Exacerbates Bleomycin-induced Lung Injury, Inflammation and Mortality. *Am J Respir Cell Mol Biol*, (2017).
26. Rosen SD, Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. *Expert Opin Ther Targets* 14, 935-949 (2010).

27. Oyoshi MK, et al. Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation. *Immunity* 37, 747-758 (2012).
28. Serezani CH, Lewis C, Jancar S, Peters-Golden M. Leukotriene B4 amplifies NF-kappaB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. *J Clin Invest* 121, 671-682 (2011).
29. Folli C, Calderone V, Ramazzina I, Zanotti G, Berni R. Ligand binding and structural analysis of a human putative cellular retinol-binding protein. *J Biol Chem* 277, 41970-41977 (2002).
30. Schultz HS, et al. OSCAR-collagen signaling in monocytes plays a proinflammatory role and may contribute to the pathogenesis of rheumatoid arthritis. *Eur J Immunol* 46, 952-963 (2016).
31. Barrow AD, et al. OSCAR is a receptor for surfactant protein D that activates TNF-alpha release from human CCR2+ inflammatory monocytes. *J Immunol* 194, 3317-3326 (2015).
32. Xu L, Cai Z, Yang F, Chen M. Activation induced upregulation of MMP9 in mast cells is a positive feedback mediator for mast cell activation. *Mol Med Rep* 15, 1759-1764 (2017).
33. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol* 4, 617-629 (2004).
34. Huang YC, Saito S, Yokoyama KK. Histone chaperone Jun dimerization protein 2 (JDP2): role in cellular senescence and aging. *Kaohsiung J Med Sci* 26, 515-531 (2010).
35. Murata T, et al. Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency. *J Biol Chem* 286, 22007-22016 (2011).
36. Hur H, Kim YB, Ham IH, Lee D. Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer. *J Surg Oncol* 112, 585-591 (2015).
37. Lakhter AJ, Hamilton J, Konger RL, Brustovetsky N, Broxmeyer HE, Naidu SR. Glucose-independent Acetate Metabolism Promotes Melanoma Cell Survival and Tumor Growth. *J Biol Chem* 291, 21869-21879 (2016).
38. Schug ZT, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. *Cancer Cell* 27, 57-71 (2015).
39. Comerford SA, et al. Acetate dependence of tumors. *Cell* 159, 1591-1602 (2014).
40. Wirschell M, et al. The nexin-dynein regulatory complex subunit DRC1 is essential for motile cilia function in algae and humans. *Nat Genet* 45, 262-268 (2013).

41. Jin W, Luo H, Wu J. Effect of reduced EPHB4 expression in thymic epithelial cells on thymocyte development and peripheral T cell function. *Mol Immunol* 58, 1-9 (2014).
42. Lu P, Shih C, Qi H. Ephrin B1-mediated repulsion and signaling control germinal center T cell territoriality and function. *Science* 356, (2017).
43. Xiong Y, et al. Annexin II receptor induces apoptosis independent of Annexin II. *Apoptosis* 18, 925-939 (2013).
44. Lohi H, et al. Functional characterization of three novel tissue-specific anion exchangers SLC26A7, -A8, and -A9. *J Biol Chem* 277, 14246-14254 (2002).
45. Dirami T, et al. Missense mutations in SLC26A8, encoding a sperm-specific activator of CFTR, are associated with human asthenozoospermia. *Am J Hum Genet* 92, 760-766 (2013).
46. Savalas LR, et al. Disrupted in renal carcinoma 2 (DIRC2), a novel transporter of the lysosomal membrane, is proteolytically processed by cathepsin L. *Biochem J* 439, 113-128 (2011).
47. Boucheron N, Ellmeier W. The role of Tec family kinases in the regulation of T-helper-cell differentiation. *Int Rev Immunol* 31, 133-154 (2012).
48. Cenni B, Gutmann S, Gottar-Guillier M. BMX and its role in inflammation, cardiovascular disease, and cancer. *Int Rev Immunol* 31, 166-173 (2012).
49. Cella M, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. *J Exp Med* 185, 1743-1751 (1997).
50. Tsubata T. Role of inhibitory BCR co-receptors in immunity. *Infect Disord Drug Targets* 12, 181-190 (2012).